Shares of Assembly Biosciences Inc (NASDAQ:ASMB) have been given an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy recommendation.

Brokers have set a 1-year consensus target price of $42.50 for the company and are forecasting that the company will post ($0.79) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Assembly Biosciences an industry rank of 230 out of 265 based on the ratings given to its competitors.

A number of equities analysts have weighed in on ASMB shares. BidaskClub raised Assembly Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, August 18th. Jefferies Group started coverage on Assembly Biosciences in a research report on Wednesday, November 8th. They set a “buy” rating and a $50.00 price target for the company. Zacks Investment Research raised Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th. ValuEngine downgraded Assembly Biosciences from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Assembly Biosciences in a research report on Sunday, September 17th.

Assembly Biosciences (NASDAQ:ASMB) traded down $2.13 during midday trading on Wednesday, reaching $41.86. The company had a trading volume of 251,200 shares, compared to its average volume of 93,026. Assembly Biosciences has a twelve month low of $11.07 and a twelve month high of $52.37.

In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $49.37, for a total transaction of $49,370.00. Following the completion of the transaction, the director now owns 20,465 shares of the company’s stock, valued at approximately $1,010,357.05. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last ninety days, insiders have sold 3,000 shares of company stock valued at $112,620. Insiders own 19.60% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the business. Nationwide Fund Advisors acquired a new stake in shares of Assembly Biosciences in the 2nd quarter valued at approximately $161,000. Parametric Portfolio Associates LLC boosted its holdings in shares of Assembly Biosciences by 13.6% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 1,203 shares during the last quarter. Legal & General Group Plc acquired a new stake in shares of Assembly Biosciences in the 2nd quarter valued at approximately $212,000. Wells Fargo & Company MN acquired a new stake in shares of Assembly Biosciences in the 2nd quarter valued at approximately $213,000. Finally, Trexquant Investment LP acquired a new stake in shares of Assembly Biosciences in the 2nd quarter valued at approximately $217,000. 62.09% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Zacks: Brokerages Set $42.50 Price Target for Assembly Biosciences Inc (ASMB)” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/12/13/zacks-brokerages-set-42-50-price-target-for-assembly-biosciences-inc-asmb.html.

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.